Zhou Lu, Wang Dongsheng, Qiu Xinjian, Zhang Weiru, Gong Zhicheng, Wang Yang, Xu Xia
Department of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, China.
Department of General Medicine, Xiangya Hospital, Central South University, Changsha, China.
Front Pharmacol. 2020 Jul 30;11:1126. doi: 10.3389/fphar.2020.01126. eCollection 2020.
Intracerebral hemorrhage (ICH) is a disease with a significantly high rate of morbidity, mortality and disability. Inhibition of inflammation is considered a potential strategy for improving the clinical symptoms induced by ICH. The hallmark of neuroinflammation is microglial activation. Microglia can polarize into either the classically activated M1 (proinflammatory) phenotype, exacerbating neuronal damage, or the alternatively activated M2 (antiinflammatory) phenotype, exerting neuroprotection and promoting neuronal recovery. Promoting microglial polarization to the M2 phenotype may be a viable strategy for treating neuroinflammation. Several studies have indicated that promoting blood circulation and removing blood stasis exhibits therapeutic effects on intracerebral hemorrhage. Dahuang Zhechong Pill (DHZCP), a classical recipe that promotes blood circulation and removes blood stasis, has been reported to improve the clinical outcome of ICH. DHZCP has been shown to exert antiinflammatory effects. However, the detailed antiinflammatory mechanism of DHZCP in ICH has rarely been investigated. In this study, DHZCP inhibited lipopolysaccharide (LPS)-induced M1 microglial activation. DHZCP exerted antiinflammatory effects, by inhibiting LPS-induced M1 proinflammatory cytokine (TNF-α and IL-6), and iNOS production and increasing M2 antiinflammatory cytokine (IL-10) production. DHZCP also switched microglial polarization from M1 to M2, as indicated by significantly increased expression of M2 polarization markers (CD209, and CD206) and markedly decreased expression of an M1 polarization marker (CD54). In addition, DHZCP inhibited p38 and TLR4/NF-κB signaling activation, as demonstrated by inhibition of LPS-induced increases in p-p38, TLR4 and nuclear factor kappa B p-65 (NF-κB p-65) protein expression. Taken together, DHZCP modulates microglial M1/M2 polarization the p38 and TLR4/NF-κB signaling pathways to confer antiinflammatory effects.
脑出血(ICH)是一种发病率、死亡率和致残率都很高的疾病。抑制炎症被认为是改善脑出血所致临床症状的一种潜在策略。神经炎症的标志是小胶质细胞激活。小胶质细胞可极化为经典激活的M1(促炎)表型,加剧神经元损伤,也可极化为替代激活的M2(抗炎)表型,发挥神经保护作用并促进神经元恢复。促进小胶质细胞向M2表型极化可能是治疗神经炎症的一种可行策略。多项研究表明,活血化瘀对脑出血具有治疗作用。大黄蛰虫丸(DHZCP)是一种活血化瘀的经典方剂,据报道可改善脑出血的临床预后。DHZCP已被证明具有抗炎作用。然而,DHZCP在脑出血中的具体抗炎机制鲜有研究。在本研究中,DHZCP抑制了脂多糖(LPS)诱导的M1小胶质细胞激活。DHZCP通过抑制LPS诱导的M1促炎细胞因子(TNF-α和IL-6)以及诱导型一氧化氮合酶(iNOS)的产生,并增加M2抗炎细胞因子(IL-10)的产生,发挥抗炎作用。DHZCP还使小胶质细胞极化从M1转变为M2,表现为M2极化标志物(CD209和CD206)的表达显著增加,而M1极化标志物(CD54)的表达明显降低。此外,DHZCP抑制了p38和TLR4/NF-κB信号通路的激活,表现为抑制了LPS诱导的p-p38、TLR4和核因子κB p-65(NF-κB p-65)蛋白表达的增加。综上所述,DHZCP通过p38和TLR4/NF-κB信号通路调节小胶质细胞的M1/M2极化,从而发挥抗炎作用。